VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2021 | Maintenance therapy after allogeneic HSCT in MDS

Francesco Onida, MD, University of Milan, Milan, Italy, gives a summary of his talk on maintenance therapy after allogeneic hematopoietic stem cell transplantation (HSCT) for patients with myelodysplastic syndromes (MDS). Dr Onida highlights the need for more data and prospective clinical trials of maintenance therapy for patients with MDS. Dr Onida also outlines the use of low-dose azacitidine and panobinostat in patients with MDS. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter